Health Care Biotech and Pharmaceuticals


  • Martin Shkreli testifies on Capitol Hill

    Former Turing Pharmaceuticals executive Martin Shkreli will appear before Congress this morning, reports CNBC's Meg Tirrell.

  • Former drug executive Martin Shkreli (R) exits with his lawyer Benjamin Brafman at the U.S. Federal Courthouse in Brooklyn, New York February 3, 2016.

    After his hearing at Brooklyn court on Wednesday, Martin Shkreli will no longer be speaking to the press according to his new lawyer.

  • Merck KGaA is a German company in the chemical and pharmaceutical industry based in Darmstadt

    Merck reported a 2.5 percent fall in quarterly revenue, hurt by a strong dollar and declining sales of its Remicade arthritis treatment.

  • Boots store

    U.K. drug store Boots has cut the prices on some of its products after it emerged it was charging women more than men for similar products.

  • Gilead shares pop 2% on earnings beat

    Gilead Sciences Q4 EPS beat analysts' expectations, reports CNBC's Meg Tirrell.

  • A scientist at Gilead Sciences analyzes patient antibody levels at the Gilead laboratory in Foster City, California.

    Gilead reported quarterly earnings and revenue on Tuesday that beat analysts' expectations, boosted by sales of its drugs in Japan.

  • Samuel Waksal

    Kadmon, the biotechnology company founded by ImClone's Sam Waksal, is preparing to file confidentially for an initial public offering, sources say.

  • An overview on the biotech sector: Pro

    Sam Isaly, OrbiMed Advisors, discusses the biotech sector and how cases like the Zika virus impact the health sector.

  • Impact of Zika Virus on Drugmakers

    A possible vaccine for the Zika virus is still three to 10 years away, says Max Macaluso, an analyst at The Motley Fool.

  • A worker fumigates the Sambadrome ahead of Carnival celebrations in Rio de Janiero, Brazil, on Tuesday, Jan. 26, 2016. The operation is part of the Health Ministry's efforts to eradicate the Aedes aegypti mosquito, which is thought to spread the Zika virus being blamed for causing birth defects.

    Tourism and travel-related stocks have taken a hit from worries surrounding the Zika virus.

  • Stopping the spread of Zika with mutant mosquitos

    The Zika virus spreads through mosquitoes and can cause feverish symptoms and even birth defects. Oxitec, a subsidiary of Intrexon, is working on a genetically modified mosquito to help combat spreading the virus, with Intrexon CEO Randal Kirk.

  • A banner is seen during an information campaign on the Zika virus by the Chilean Health Ministry at the departures area of Santiago's international airport, Chile, January 28, 2016.

    The Zika virus should not cause Americans to be "unduly alarmed just yet," says infectious disease expert Paul Roepe.

  • A scientist at Gilead Sciences analyzes patient antibody levels at the Gilead laboratory in Foster City, Calif.

    Gilead Sciences on Friday that John Milligan, currently president and chief operating officer, will be promoted to CEO and appointed to the board of directors.

  • Amgen

    Amgen boosted guidance after it beat on fourth-quarter earnings, helped by sales of its rheumatoid arthritis drug Enbrel.

  • Drug companies can't bankrupt states: Mass. AG

    Massachusetts Attorney General Maura Healey explains why it's worth investigating drug pricing and Gilead's practices.

  • Martin Shkreli and Rapper Ghostface Killah of the Wu-Tang Clan.

    The rap-fueled beef with Ghostface Killah was recorded while the pharma exec Martin Shkreli is free on $5 million bond.

  • Like big pharma, biotech is toxic: Trader

    Health care is one of the biggest drags on the market right now because of the moves lower in biotech stocks. CNBC's Meg Tirrell looks ahead to biotech earnings out next week. The FMHR traders and Kate Moore, JPMorgan Private Bank chief investment strategist, discuss.

  • Theranos under fire

    Regulators warn that new Theranos lab in California is unsafe for patients, company says it's taking corrective action. CNBC's Meg Tirrell explains.

  • Roche earnings miss forecasts

    Severin Schwan, CEO of Roche, discusses his company's full year results, which came in below expectations.

  • The rapid spread of the zika virus has spurred the hunt for a cure, but the financial incentive and likely length of time for a vaccine are unclear.

Contact Biotech and Pharma


    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    Get these newsletters delivered to your inbox, and more info about about our products and service. Privacy Policy.


  • Dan Mangan is a reporter covering health care for

  • Meg Tirrell joined CNBC in April 2014 as a general assignment reporter focusing on biotechnology and pharmaceuticals.

  • Bertha Coombs

    Bertha Coombs is a general assignment reporter for CNBC, covering financial markets and business news stories.